Analyst Price Targets — CRLBF
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 20, 2022 8:37 am | — | Cowen & Co. | $2.50 | $2.23 | Benzinga | Cowen & Co. Downgrades Cresco Labs to Market Perform, Lowers Price Target to $2.5 |
| December 2, 2022 2:32 pm | Gerald Pascarelli | Wedbush | $8.50 | $3.80 | Benzinga | Wedbush Initiates Coverage On Cresco Labs, Curaleaf Holdings With Outperform Ratings |
Latest News for CRLBF
Cresco's 10% monthly rally reflects stronger revenues, organic growth and margins, but competition and normalization risks cloud the outlook.
CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”) today announced the closing of its acquisition of 100% of the outstanding equity interests in PharmaCann Penn, LLC (“PharmaCann”) for an aggregate consideration of US$50 million (the “Transaction”). The Transaction consists of nine operational retail medical marijuana dispensaries in Pennsylvania,…
What will help marijuana stock investors trade more, even in the midst of laws changing in the USA? It is no secret that nothing has moved pot stocks more than news of global reform or regulatory matters. For the US, what happens at the federal level has moved the needle the most, with the recent passing of legislation to reclassify cannabis to Schedule 3.
Cresco Labs Inc. (CRLBF) Q2 2026 Earnings Call Transcript
Cresco Labs Inc. (CRLBF) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.05 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for CRLBF.
Senate Trading
No Senate trades found for CRLBF.
U.S. House Trading
No House trades found for CRLBF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.